Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| insulin-like growth factors | 5009 | 68562-41-4 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Recombinant form of endogenous Insulin-like Growth Factor 1 exhibiting mitogenic activity. Clinical Use: Diabetes Mellitus and Amyotrophic Lateral Sclerosis.
|
| Dose | Unit | Route |
|---|---|---|
| 2 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 30, 2005 | FDA | IPSEN INC | |
| March 8, 2007 | EMA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypoglycaemia | 73.07 | 40.51 | 21 | 302 | 69827 | 90558297 |
| Tonsillar hypertrophy | 45.05 | 40.51 | 7 | 316 | 1165 | 90626959 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tonsillar hypertrophy | 151.35 | 48.00 | 24 | 731 | 901 | 42619679 |
| Product dose omission issue | 65.58 | 48.00 | 38 | 717 | 154327 | 42466253 |
| Hypoglycaemia | 65.21 | 48.00 | 28 | 727 | 59826 | 42560754 |
| Adenoidal hypertrophy | 54.23 | 48.00 | 8 | 747 | 182 | 42620398 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tonsillar hypertrophy | 171.70 | 40.91 | 27 | 968 | 1911 | 110586393 |
| Hypoglycaemia | 126.37 | 40.91 | 45 | 950 | 116059 | 110472245 |
| Product dose omission issue | 71.31 | 40.91 | 41 | 954 | 321741 | 110266563 |
| Adenoidal hypertrophy | 57.98 | 40.91 | 8 | 987 | 226 | 110588078 |
| Papilloedema | 50.46 | 40.91 | 12 | 983 | 7397 | 110580907 |
| Snoring | 46.26 | 40.91 | 11 | 984 | 6773 | 110581531 |
None
| Source | Code | Description |
|---|---|---|
| ATC | H01AC03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists |
| MeSH PA | D006133 | Growth Substances |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:50779 | appetite enhancer |
| CHEBI has role | CHEBI:176497 | geroprotector |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Laron-type isolated somatotropin defect | indication | 38196001 | DOID:9521 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Insulin-like growth factor 1 receptor | Kinase | AGONIST | IC50 | 8.31 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Insulin receptor | Kinase | IC50 | 5.85 | SCIENTIFIC LITERATURE |
| ID | Source |
|---|---|
| D03297 | KEGG_DRUG |
| 4024932 | VUID |
| N0000023113 | NUI |
| 4024932 | VANDF |
| CHEBI:749581 | CHEBI |
| CHEMBL1201716 | ChEMBL_ID |
| C000604197 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB01277 | DRUGBANK_ID |
| 274403 | RXNORM |
| 20506 | MMSL |
| 71163 | MMSL |
| d05636 | MMSL |
| 011016 | NDDF |
| 418157000 | SNOMEDCT_US |
| 418845006 | SNOMEDCT_US |
| 5699003 | SNOMEDCT_US |
| C0904505 | UMLSCUI |
| 6372 | INN_ID |
| 4971 | IUPHAR_LIGAND_ID |
| 7GR9I2683O | UNII |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Increlex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 15054-1040 | INJECTION, SOLUTION | 40 mg | SUBCUTANEOUS | BLA | 28 sections |
| Cosmeceutical Mask Pack | HUMAN OTC DRUG LABEL | 6 | 60709-102 | PATCH | 0.04 mg | TOPICAL | unapproved drug other | 9 sections |
| Dermaheal Cosmeceutical Mask Pack Plus | HUMAN OTC DRUG LABEL | 6 | 60709-105 | PATCH | 0.04 mg | TOPICAL | unapproved drug other | 9 sections |
| Increlex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71863-216 | INJECTION | 40 mg | SUBCUTANEOUS | BLA | 32 sections |
| Increlex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71863-216 | INJECTION | 40 mg | SUBCUTANEOUS | BLA | 32 sections |